CT-X antigen expression in human breast cancer

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Cancer/testis (CT) genes are primarily expressed in germ cells but aberrantly activated in various cancers.
• CT antigens serve as valuable biomarkers and therapeutic targets for cancer vaccines.
• Expression patterns of CT antigens in breast cancer remain incompletely understood.

Purpose of the Study:

• To investigate the expression profile of CT antigens on the X chromosome (CT-X) in breast cancer.
• To determine the correlation between CT-X antigen expression and breast cancer subtypes, particularly estrogen receptor (ER) status.

Main Methods:

• Analysis of previously generated massively parallel signature sequencing (MPSS) data.
• Integration and analysis of 9 publicly available gene expression datasets.
• Immunohistochemical staining of primary breast tumors to validate expression patterns.

Main Results:

• CT-X antigen transcripts were detected in a subset of breast cancers, with significantly higher frequency in ER-negative cell lines and primary tumors.
• A coordinated expression pattern was observed, with MAGEA and NY-ESO-1/CTAG1B being the most prevalent CT-X antigens.
• Immunohistochemistry confirmed the association of CT-X antigen expression with ER negativity and a trend towards coexpression with basal cell markers.

Conclusions:

• CT-X antigens are frequently expressed in ER-negative breast cancers, highlighting a potential therapeutic vulnerability.
• The prevalence and coordinated expression of MAGEA and NY-ESO-1/CTAG1B suggest their utility as biomarkers.
• CT-X antigen-based vaccines represent a promising therapeutic strategy for ER-negative breast cancers, addressing a critical unmet need.